Vanda Pharmaceuticals Inc (Nasdaq: VNDA), a Washington D.C.-based biopharmaceutical company, announced on Friday that NEREUS (tradipitant) is now commercially available across the United States for the prevention of vomiting induced by motion in adults.

According to the company, this marks the first new prescription medicine approved for this condition in more than 40 years. An innovative direct-to-consumer order platform is now available through nereus.us.

Motion sickness affects an estimated 65 to 78 million Americans - roughly 25% to 30% of adults - during everyday travel by car, plane or boat.

Vanda says that NEREUS is available now by prescription directly through nereus.us and retail pharmacies nationwide. Through the dedicated direct-to-consumer portal at nereus.us, patients with a valid prescription can access NEREUS at a cash-pay price of USD85 per dose, a discount from the standard list price of USD255 per dose.

The U.S. Food and Drug Administration approved NEREUS on 30 December 2025, following two pivotal Phase 3 clinical trials - Motion Syros and Motion Serifos - conducted under real-world conditions on the open sea.

According to Vanda, both studies demonstrated that NEREUS significantly prevented vomiting compared to placebo, confirming the drug's effectiveness in actual sea travel conditions.